Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE:EW) common stock between April 25, 2012 and April 23, 2013.
For more information, click here:
The complaint alleges that the Company made false/misleading statements and/or failed to disclose material information related to the Company’s projected sales, financial prospects, and adoption of the Company’s SAPIEN transcatheter aortic heart valve. In particular, it is alleged that the Company knew but concealed that: a) due to physicians’ concerns over the risks and complexity of the procedure for implanting SAPIEN, adoption of SAPIEN was weaker than the Company claimed; b) the Company’s outlook for sales and earnings per share was significantly weaker than suggested to investors; and c) as a result of the aforementioned, the Company lacked a reasonable basis for its statements relating to the Company’s operations, forecasts, and outlook.
If you suffered a loss in Edwards Lifesciences you have until November 18, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.